B Biogen News Today

in a century. history going on here. welcome to another hour of "americas newsroom." im dana perino. >> bill: missed you. happy new year. >> dana: i missed you. are you glad to be back? >> bill: with you absolutely. im bill hemmer. happy new year at home. the house is getting ready to end the 117th congress. the senate will do the same later this morning. the new house could convene in about two hours, 12 noon with a vote for speaker expected to begin around 1:00 eastern time. >> dana:...

Drug. now take a look at this from the investigation. it finds that was an unjust fileably high price according to congress. dem democrat is said it is straight up corporate greed. they hope this report will be a wake-up call for the fda to reform. right now the fda is re-evaluating two alzheimers drugs. one was developed in part by biogen. >> bill: very interesting. gillian turner in washington, d.c. >> dana: as americas crime crisis continues one democrat-led state is making it harder for poli...

Deviated from fda guidance and procedures in significant respects. they are accusing the fda of working with biogen, the manufacturer of the drug, to approve the drug, promote it and rush it to market. even putting together joint presentations between the fda and biogen advocating for the drugs effectiveness. the fda not acknowledging any wrongdoing but doubling down on their practices. quote, fda remains committed to the integrity of our drug approval process and will continue to use the accele...

In July 2020, almost a year before Biogen's dementia medication Aduhelm was approved, the company convened a meeting of advocates and experts to discuss "strategies to help communities of color address dementia."

The first new Alzheimer's treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works.

The first new Alzheimer's treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works.